Captopril disulfide
Based on 1 Customer Validation
Captopril disulfide (SQ 14551) is an orally active disulfide dimer prodrug. Captopril disulfide is metabolized to Captopril and acts as a Bradykinin potentiator. Captopril disulfide enhances the vasodilatory effect of Bradykinin in anesthetized rats and the contractile response of isolated guinea pig ileum to Bradykinin. Captopril disulfide exhibits antihypertensive activity in spontaneously hypertensive rats. Captopril disulfide can be used in hypertension-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.29%
- CAS No.: 64806-05-9
- Formule: C18H28N2O6S2
- Masse moléculaire:432.55
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-123068R
Captopril disulfide (Standard)ACE Inhibitor -
HY-10108
LY294002PI3K Inhibitor -
HY-B0279
RamiprilApoptosis Inducer -
HY-P1032
Angiotensin I (human, mouse, rat)Decapeptide Hormone -
HY-10108R
LY294002 (Standard)PI3K Inhibitor -
HY-19414
MLN-4760ACE2 Inhibitor -
HY-B0331A
Enalapril maleateAngiotensin-Converting Enzyme Inhibitor -
HY-B0231
Enalaprilat dihydrateACE Inhibitor -
HY-B0382
Fosinopril sodiumACE Inhibitor -
HY-168376
9(10)-NitrooleateAkt Activator -
HY-18206A
Lisinopril dihydrateACE Inhibitor -
HY-A0116R
Trandolaprilate (Standard)ACE Inhibitor
Activité biologique
Description
In Vitro
Captopril disulfide (0.1-10 μM) potentiates 0.01 μM bradykinin-induced contractions in isolated guinea pig ileum, with no significant activity at 0.1 μM and 1.0 μM, a 285% of control potentiation at 10 μM, and an EC50 of 3.0 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
Captopril disulfide (0.1-1.0 mg/kg; i.v.; single bolus) enhances bradykinin-induced vasodilation in anesthetized rats[2].
Captopril disulfide (10 mg/kg; p.o.; single administration) exerts a significant hypotensive effect in spontaneously hypertensive rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (either sex, 140-220 g)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose; i.v.; single dose
-
Result:Rapidly generated active captopril monomers, and captopril-like substances accumulate in the kidneys, liver, and lungs.
-
Animal Model:Sprague-Dawley (male, 220-280 g, urethane-anesthetized normotensive)[2]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1.0 mg/kg
-
Administration:i.v.; single bolus
-
Result:Caused 25% blockade of AI pressor responses at 0.3 mg/kg.
Caused AI pressor response blockade similar to captopril at 1.0 mg/kg.
Increased Bradykinin-mediated vasodepressor response amplitude to 132% of control (32% potentiation) and prolonged duration to 128% of control at 0.1 mg/kg.
Increased BK-mediated vasodepressor response amplitude to 285% of control (185% potentiation) and prolonged duration to 112% of control at 0.3 mg/kg.
Increased BK-mediated vasodepressor response amplitude to 225% of control and prolonged duration to 135% of control at 1.0 mg/kg.
Required a dose of 0.11 mg/kg to potentiate BK amplitude by 50% of maximum response, 0.08 mg/kg to potentiate BK duration by 50% of maximum response, and 0.8 mg/kg to inhibit AI responses by 50%.
-
Animal Model:Spontaneously hypertensive rat (SHR) (male, 240-280 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Caused a small blood pressure reduction at 30 minutes post-dose, with peak effects at 6 hours: systolic blood pressure fell by 46 mmHg, and diastolic blood pressure fell by 32 mmHg.
Produced reductions not statistically different from those induced by captopril at the same dose.
Allowed blood pressures to return to pre-dose values by 24 hours post-dose.
Chemical Information
-
CAS No. 64806-05-9
-
Appearance Solid
-
Masse moléculaire 432.55
-
Formule C18H28N2O6S2
-
Color White to off-white
-
SMILES
O=C([C@@H](CSSC[C@H](C(N1[C@H](C(O)=O)CCC1)=O)C)C)N2[C@H](C(O)=O)CCC2
-
Synonyms
SQ 14551
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
In Vitro:
DMSO : 116.67 mg/mL (269.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Drummer OH, et al. Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. Biochem Pharmacol. 1984;33(22):3567-3571. [Content Brief]
[2]. Drummer OH, et al. Bradykinin-potentiating activity of captopril disulphide dimer (SQ 14,551). Eur J Pharmacol. 1988;153(1):11-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3119 mL | 11.5594 mL | 23.1187 mL | 57.7968 mL |
| 5 mM | 0.4624 mL | 2.3119 mL | 4.6237 mL | 11.5594 mL | |
| 10 mM | 0.2312 mL | 1.1559 mL | 2.3119 mL | 5.7797 mL | |
| 15 mM | 0.1541 mL | 0.7706 mL | 1.5412 mL | 3.8531 mL | |
| 20 mM | 0.1156 mL | 0.5780 mL | 1.1559 mL | 2.8898 mL | |
| 25 mM | 0.0925 mL | 0.4624 mL | 0.9247 mL | 2.3119 mL | |
| 30 mM | 0.0771 mL | 0.3853 mL | 0.7706 mL | 1.9266 mL | |
| 40 mM | 0.0578 mL | 0.2890 mL | 0.5780 mL | 1.4449 mL | |
| 50 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1559 mL | |
| 60 mM | 0.0385 mL | 0.1927 mL | 0.3853 mL | 0.9633 mL | |
| 80 mM | 0.0289 mL | 0.1445 mL | 0.2890 mL | 0.7225 mL | |
| 100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.5780 mL |
Captopril disulfide Related Classifications
HY-123068 Related Classifications
Powered by Bioz